INDUSTRY NEWS
Arthur Cummings
Published: Tuesday, March 3, 2015
Nicox S.A. has announced the signature of a licence agreement with InSite Vision Inc. for the development, manufacture and commercialisation of InSite’s innovative ophthalmic therapeutics AzaSite® (one per cent azithromycin), BromSiteTM (0.075 per cent bromfenac) and AzaSite XtraTM (two per cent azithromycin).
All three products are based on InSite’s proprietary Durasite® drug delivery technology, which is designed to extend the duration of a drug in the eye. The agreement grants Nicox exclusive rights to all three products in Europe, Middle East and Africa. European Marketing Authorisation Applications (MAAs) for AzaSite® and BromSiteTM are expected to be filed by Q1 2016.
www.nicox.com
Latest Articles
ESCRS Today 2025: Happy Anniversaries!
ESCRS celebrates milestones with pioneers in IOLs, LASIK, femtosecond lasers, and corneal transplantation.
ESCRS Today 2025: A Congress for Everyone
From YOs to families, the ESCRS Annual Meeting embraces full participation through inclusivity.
Beyond the Numbers
Empowering patient participation fosters continuous innovation in cataract surgery.
Thinking Beyond the Surgery Room
Practice management workshop focuses on financial operations and AI business applications.
Aid Cuts Threaten Global Eye Care Progress
USAID closure leads retreat in development assistance.
Supplement: ESCRS Clinical Trends Series: Presbyopia
Debate: FS-LASIK or KLEx for Hyperopia?
FS-LASIK has more of a track record, but KLEx offers advantages.
Four AI Applications Ready for Practice
Commercial offerings may save time, improve practice and research.
Perioperative Medication Regimens for Cataract Surgery
Randomised controlled clinical trial results provide evidence-based guidance.